PharmaFluidics launches next-generation µPAC™ technology for routine proteomics

PharmaFluidics NV, innovative life sciences instruments player, is excited to announce a step-change in its product offering, extending the range with its next-generation µPAC™ nano-LC chips, preferred workhorses for routine proteomics.

With its innovative silicon circuit designs and the use of manufacturing techniques from the micro-chip industry, PharmaFluidics’ µPAC™ micro-fluidic chips address a high unmet need to separate and analyze complex biological samples into thousands of components. These allow for better, more standardized workflows to study and monitor the health condition and possible pathologies of the human body, such as cancer, autoimmune, and metabolic disease patterns, constituting entry points to personalized medicine.

“The precision patterned and extremely reproducible µPAC™ microfluidic chips are conducive to generate high-quality biological data. With the further downscaling of the critical design dimensions by a factor of 2 in our second-generation technology, we are now definitely opening a new league in high-resolution unbiased proteomics” Paul Jacobs, co-founder and COO at PharmaFluidics commented.

“Given the performance and versatility of our µPAC™ technology platform, PharmaFluidics also looks beyond proteomics to cover many additional opportunities in biopharmaceutical analysis & process monitoring, clinical studies, and routine quality control applications”, added Johan Devenyns, CEO.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>